Dermnet Videos
Nonmelanoma skin cancers Videos
- Basal Cell Nevus Syndrome
- Mohs’s Micrographic Surgery
- Sclerosing or Morpheaform Basal Cell Carcinoma
- Skin Cancer Basal Cell Carcinoma
- Skin Cancer Basal Cell Carcinoma Histology
- Skin Cancer Basal Cell Carcinoma Superficial Basal Cell Carcinoma
- Skin Cancer Basal Cell Carcinoma Treatment
- Skin Cancer Nodular Basal Cell Carcinoma
- Skin Cancer Pigmented Basal Cell Carcinoma
- Skin Cancer Cutaneous T-cell Lymphoma Definition and Description
- Skin Cancer Cutaneous T-cell Lymphoma Erythrodermic stage (Sezary syndrome)
- Skin Cancer Cutaneous T-cell Lymphoma Hematology and pathology
- Skin Cancer Cutaneous T-cell Lymphoma Patch Stage
- Skin Cancer Cutaneous T-cell Lymphoma Plaque stage
- Skin Cancer Cutaneous T-cell Lymphoma Stages
- Skin Cancer Cutaneous T-cell Lymphoma Treatment
- Skin Cancer Cutaneous T-cell Lymphoma Tumor stage
- Skin Cancer Squamous Cell Carcinoma
- Skin Cancer Squamous Cell Carcinoma Appearance
- Skin Cancer Squamous Cell Carcinoma Keratoacanthoma Variant
- Skin Cancer Squamous Cell Carcinoma of the Arms and Legs
- Skin Cancer Squamous Cell Carcinoma Relationship to HPV
- Skin Cancer Squamous Cell Carcinoma Transplant Patients
- Skin Cancer Squamous Cell Carcinoma Treatment
Video Topics
Skin Cancer Squamous Cell Carcinoma of the Arms and Legs
Marjolin’s ulcer is a term that refers to malignant changes occurring in chronic ulcers and wounds of the skin, sinuses and previous burns. Most lesions are reported in burns. The majority of these lesions are found on the extremities. Development times for burn scar carcinomas of more than 30 years have been noted. Different cultures appear to have markedly different susceptibilities to Marjolin’s ulcer. Japan, Northern India, and China report high incidences of burn-scar carcinoma.
SCCs that occur at sites of chronic inflammation are more aggressive than those that develop from actinic keratoses or Bowen’s disease. Their appearance is masked by inflamed hypertrophic tissue. The overall metastatic rate is greater than 40%. The incidence of regional lymph node involvement from burn-scar carcinoma is approximately 35%. The 5-year survival rate for lower extremity lesions is approximately 30%.
Because of the focal nature of malignant change in burn scars, excisional biopsy should be performed. Punch biopsies may be negative.
Wide local excision has proven unreliable for grade II and grade III disease; amputation and prophylactic node irradiation is recommended. Wide local excision is reserved only for very small lesions that can be radically excised or for grade I lesions.